A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 — but only if between two and ...

In the latest trading session, Gilead Sciences (GILD) closed at $105.25, marking a +2% move from the previous day. The stock lagged the S&P 500's daily gain of 9.52%. Elsewhere, the Dow saw an upswing ...

Gilead legal chief, leaves Cytokinetics after 7 months as CLO. His exit comes as the biotech awaits FDA decision on a heart ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...

Human immunodeficiency virus, if untreated, causes acquired immunodeficiency syndrome (AIDS), and death. HIV is almost entirely preventable by using condoms, or by taking PrEP drugs. PrEP drugs do not ...

While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its ...

In people with HIV taking antiretroviral therapy, excessive visceral abdominal fat drives cardiovascular disease risk, even ...